Antianginal efficacy and improved exercise performance with timolol

摘要: Antianginal efficacy and improved exercise performance with timolol, a new beta-adrenergic blocking agent, was assessed in 23 patients chronic stable angina pectoris an 11-week double-blind, placebo-controlled study. Twenty-two of the subjects completed open-label phase this investigation (weeks 0 to 6) while receiving 10 30 mg timolol twice daily optimize capacity. Weekly anginal episodes nitroglycerin consumption declined from 8.9 ± 9.1 episodes/week 8.1 10.6 tablets/week, respectively, placebo 2.7 5.2 2.6 6.0 tablets/week optimal dose (p −3 versus 21.7 5.4 × , respectively). Exercise duration prolonged 263.3 90.2 seconds 330.3 73.9 During double-blind 7 10), 8 received 11 placebo. Nitroglycerin at weeks frequency week were unchanged compared initial treatment. Resting HR, peak double product significantly attenuated their exposure. However, these variables therapy. again results (315.1 61.2 261.3 68.8 seconds, p Timolol daily, therefore, is potentially useful some pectoris. Other may, however, require shorter interval for control maximal improvement